Subscribe
ptab-bass
Lenka Horavova/shutterstock.com
25 August 2015Americas

PTAB shoots down Kyle Bass IPR request

Hedge fund manager Kyle Bass has been dealt a blow after failing to invalidate two patents owned by biotechnology company Acorda Therapeutics.

Already registered?

Login to your account

To request a FREE 2-week trial subscription, please signup.
NOTE - this can take up to 48hrs to be approved.

Two Weeks Free Trial

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk


More on this story

Americas
Bass suffers another IPR setback
3 September 2015   Hedge fund manager Kyle Bass’s Coalition for Affordable Drugs has suffered another setback in its bid to knock out allegedly spurious patents after the US Patent and Trademark Office declined to institute an inter partes review of a patent owned by Biogen.


Editor's picks

Americas
Trump’s return sparks calls for pro-patent agenda
5 December 2024

Editor's picks

Americas
Trump’s return sparks calls for pro-patent agenda
5 December 2024
Americas
Comparing life sciences IP in Brazil and the US
28 November 2024
Americas
UPC bans Meril Life Sciences from selling infringing heart valve
19 November 2024
Americas
Amgen set for ‘at-risk’ launch of blockbuster eye drug biosimilar
24 October 2024
Americas
Big Pharma counsel embrace AI but data and legal risks loom
24 October 2024
Asia
President Xi sends message to AIPPI’s World Congress
22 October 2024

More on this story

Americas
Bass suffers another IPR setback
3 September 2015   Hedge fund manager Kyle Bass’s Coalition for Affordable Drugs has suffered another setback in its bid to knock out allegedly spurious patents after the US Patent and Trademark Office declined to institute an inter partes review of a patent owned by Biogen.

More on this story

Americas
Bass suffers another IPR setback
3 September 2015   Hedge fund manager Kyle Bass’s Coalition for Affordable Drugs has suffered another setback in its bid to knock out allegedly spurious patents after the US Patent and Trademark Office declined to institute an inter partes review of a patent owned by Biogen.

More features

Takeda loses AMR treatment patent used in kidney transplants
Withers & Rogers hires cell and gene therapy expert
Medtech firm strikes out part of Apple button patent in ECG row
Tissue repair VP gets new trial over secrets damages
Labcorp's bid to invalidate Ravgen's DNA testing patent hits roadblock
Troutman Pepper Locke exodus sees teams leave in Chicago and London
Ex-Baker McKenzie patent litigation head joins Morgan Lewis in Germany
Mitsubishi Tanabe takes on Indian generic drugmaker’s ALS application